Democrats in the U.S. House of Representatives and eight advocacy groups are pressing Department of Health and Human Services (HHS) head Xavier Becerra to use either “march-in” or government use rights for the prostate cancer drug Xtandi, which is marketed by Pfizer and Japanese company Astellas but was developed using grant funding from the U.S. Army and the National Institutes of Health (NIH).
Source: Drug Industry Daily